companydata.dkcompanydata.dk

Drug Development Consulting Holding ApS: Financial statements 2023

CVR: 42285722

Source: annual report 2023, Danish Business Authority

01/01/2023 – 31/12/2023

Drug Development Consulting Holding ApS (CVR 42285722) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK -53,330 and a net result of DKK -9,376,330 compared with DKK -11,874,000 the year before. Equity in the 2023 report amounted to DKK 70,460,370. The solvency ratio was 100%. The company had 164 employees in the financial year.

Gross Profit
DKK -53,330
Profit/Loss
DKK -9,376,330
Equity
DKK 70,460,370
Total Assets
DKK 70,482,000
Employees
164

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2023--53K-9.4M70.5M164
2022--58K-11.9M72M184

Official annual report

View the official annual report directly on the page with a Pro subscription.

Fetch this data via API

Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.

See the API documentation

Events in 2023

Drug Development Consulting Holding ApS: The 2022 annual report is outJun 16, 2023

Drug Development Consulting Holding ApS has published its annual report for 2022. Gross profit came to DKK -58,000, and the net result was DKK -11,874,000.

René Holmen Pedersen joins Drug Development Consulting Holding ApS as directorJun 1, 2023

As of June 1, 2023, René Holmen Pedersen is registered as director of Drug Development Consulting Holding ApS.

Rasmus Koch Nelund joins Drug Development Consulting Holding ApS as directorMay 1, 2023

As of May 1, 2023, Rasmus Koch Nelund is registered as director of Drug Development Consulting Holding ApS.

Alejandra Maria Cristina Bonifacini Mørk steps down as director of Drug Development Consulting Holding ApSApr 30, 2023

As of April 30, 2023, Alejandra Maria Cristina Bonifacini Mørk has stepped down as director of Drug Development Consulting Holding ApS.

Niels Peder Nielsen joins the board of Drug Development Consulting Holding ApSFeb 22, 2023

As of February 22, 2023, Niels Peder Nielsen has joined the board of directors of Drug Development Consulting Holding ApS.

Rafael Natanek joins the board of Drug Development Consulting Holding ApSFeb 22, 2023

As of February 22, 2023, Rafael Natanek has joined the board of directors of Drug Development Consulting Holding ApS.

Rafael Natanek leaves the board of Drug Development Consulting Holding ApSFeb 21, 2023

As of February 21, 2023, Rafael Natanek has left the board of directors of Drug Development Consulting Holding ApS.

About Drug Development Consulting Holding ApS

Drug Development Consulting Holding ApS is a Danish company of the type Anpartsselskab based in Brøndby, founded in 2021. The company is registered under the industry Ikke-finansielle holdingselskaber. The management consists of René Holmen Pedersen. The board consists of Niels Peder Nielsen (chair), Alejandra Maria Cristina Bonifacini Mørk, Rafael Natanek and Redmar Koene. The company is owned by DDC Mørk Holding ApS and GHS III Midco B.V.. According to the 2025 annual report, the company had an average of 122 employees. In 2025, the company reported a gross profit of DKK -92,000 and a net result of DKK -61,449,000 compared with DKK -13,302,000 the year before. Equity in the 2025 report amounted to DKK 32,586,000.

Source: annual report 2025, Danish Business Authority

Other financial years